Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
BACKGROUND: A number of important scientific advances can be made through the study of blood,
 bone marrow, tumor, or other tissue samples from patients with HIV infection, infection with
 Kaposi s sarcoma associated herpesvirus (KSHV), infection with other oncogenic viruses, or
 cancer. This protocol provides a mechanism to effect a variety of such studies.

 OBJECTIVES: Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue
 samples from patients with HIV infection, KSHV infection, or with cancer.

 ELIGIBILITY: Eligibility criteria include age 18 years or older and at lest one of the
 following: Exposure risk to HIV, KSHV, or HPV; HIV seropositive; KSHV seropositive; EBV
 seropositive; HTLV-1 seropositive; malignancy, Castleman s disease, or skin lesions with
 appearance of Kaposi s sarcoma; or cervical or anal intraepithelial lesion.

 DESIGN: Blood samples may be collected at the initial visit, and at follow-up visits. Tumor
 samples may be obtained by fine needle aspirate, by removal of pleural or peritoneal fluid,
 by skin punch biopsy, or by excisional biopsy, providing the tumor is accessible with minimal
 risk to the patients. Specific risks will be described in a separate consent to be obtained
 at the time of the biopsy. Samples will be studied in the HIV and AIDS Malignancy Branch,
 CCR, NCI; laboratories in NCI-Frederick; or those of collaborating investigators.

 ...
BACKGROUND:

 -  A number of important scientific advances can be made through the study of blood, bone
 marrow, tumor, or other tissue samples from patients with HIV infection, infection with
 Kaposi s sarcoma associated herpesvirus (KSHV), infection with other oncogenic viruses,
 or cancer.

 -  This protocol provides a mechanism to effect a variety of such studies.

 OBJECTIVES:

 -Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue samples
 from patients with HIV infection, KSHV infection, or with cancer.

 ELIGIBILITY:

 -Eligibility criteria include age 18 years or older and at least one of the following:
 Exposure risk to HIV, KSHV, or HPV; HIV seropositive; KSHV seropositive; EBV seropositive;
 HTLV-1 seropositive; malignancy, Castleman s disease, or skin lesions with appearance of
 Kaposi s sarcoma; or cervical or anal intraepithelial lesion.

 DESIGN:

 -  Blood samples may be collected at the initial visit, and at follow-up visits.

 -  Tumor samples may be obtained by fine needle aspirate, by removal of pleural or
 peritoneal fluid, by skin punch biopsy, or by excisional biopsy, providing the tumor is
 accessible with minimal risk to the patients.

 -  Specific risks will be described in a separate consent to be obtained at the time of the
 biopsy.

 -  Samples will be studied in the HIV and AIDS Malignancy Branch, CCR, NCI; laboratories in
 NCI-Frederick; or those of collaborating investigators.
-  INCLUSION CRITERIA:

 -  Age 18 years or older.

 -  ECOG performance status less than or equal to 3.

 At least one of the following:

 -  Exposure risk to HIV, KSHV, or HPV

 -  HIV seropositive

 -  KSHV seropositive

 -  EBV seropositiv

 -  HTLV-1 seropositive

 NOTE: infection with HIV, KSHV, EBV, and HTLV-1 are life-long, so if patients have
 previously been seropositive or have had a disease associated with KSHV (KS, primary
 effusion lymphoma [PEL], or KSHV-multicentric Castleman s disease), this is sufficient to
 meet this criterion for eligibility.

 -  Malignancy, Castleman's disease, or skin lesions with appearance of Kaposi's sarcoma

 -  Cervical or anal intraepithelial lesion

 EXCLUSION CRITERIA:

 Inability to provide informed consent.